Login
AMGEN INC logo

AMGEN INC

amgen.com

What Do They Do?

Sells medicines for cancer, inflammatory conditions and other diseases to healthcare providers and pharmaceutical wholesalers.

How Do They Make Money?

Amgen earns most of its revenue from selling medicines, with payment generally due after shipment. Other revenue comes mainly from royalties on licensed products and collaboration license fees, milestones and shares of commercial profits.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Product sales
Sold outright

96%
FY2022: 94%
Other revenues
4.4%
FY2022: 5.8%

Who Are Their Customers?

In the United States, Amgen sells mainly to pharmaceutical wholesale distributors, which supply healthcare providers. Outside the United States, it sells mainly to healthcare providers or pharmaceutical wholesale distributors, based on local distribution practices; collaborators also help market medicines to providers.

Customers above 10% of revenue, FY2025
of revenue from three customers (34%, 27%, 16%)
FY2023: 79% from three customers

Do Revenues Turn Into Profits?

Yes. It kept 21 cents of every revenue dollar as net income in FY2025 and turned 22 cents into free cash flow.

Operating income, FY2025
25% of revenue
▲ +25% vs FY2024 ($7.3B, 22%)
Net income, FY2025
21% of revenue
▲ +89% vs FY2024 ($4.1B, 12%)
Free cash flow, FY2025
22% of revenue
▼ −22% vs FY2024 ($10.4B, 31%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +8%
vs $9.6B in Q3 FY2025
Net income
▲ +20%
vs $3.2B in Q3 FY2025
Product sales share of revenue vs 95.6% in Q3 FY2025
  • Jul 31, 2026 Amgen disclosed a data theft from third-party cloud environments Some company, patient and other information was exfiltrated; Amgen reported no identified impact on products, manufacturing or financial reporting systems.
  • May 19, 2026 Thomas Dittrich succeeded Peter Griffith as chief financial officer Griffith announced his retirement, and Dittrich became CFO effective September 1, 2026.

Growing. Revenue grew 41% in 4 years, from $26B in FY2021 to $36.8B in FY2025, about 9% a year.

More medicines for additional uses The latest report describes expanded uses and approvals for marketed medicines, including UPLIZNA, TEZSPIRE, Repatha and IMDELLTRA. The older report focused on earlier trial results and approvals for products such as TEZSPIRE.

Wider product range The latest report names a broader set of marketed products, including TEPEZZA, KRYSTEXXA, UPLIZNA and IMDELLTRA/IMDYLLTRA, alongside its principal products. The older report described a smaller set of selected marketed products.

Revenue over time
Product sales Other revenues
$50B$25B$0

Who Do They Compete With?

Competes with Regeneron Pharmaceuticals, Sanofi, Eli Lilly and, Bristol Myers Squibb, Pfizer, Asahi Kasei Pharma, AstraZeneca, GSK, Genentech, Celgene, Takeda Oncology, Legend Biotech, F. Hoffmann-La Roche, and Merck &

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support